Therapeutic potential of cannabinoids in the management of Alzheimer\u27s Disease and other neurodegenerative conditions by Ramos, Lauren
Creative Components Iowa State University Capstones, Theses and Dissertations 
Fall 2019 
Therapeutic potential of cannabinoids in the management of 
Alzheimer's Disease and other neurodegenerative conditions 
Lauren Ramos 
laurenw@iastate.edu 
Follow this and additional works at: https://lib.dr.iastate.edu/creativecomponents 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Ramos, Lauren, "Therapeutic potential of cannabinoids in the management of Alzheimer's Disease and 
other neurodegenerative conditions" (2019). Creative Components. 418. 
https://lib.dr.iastate.edu/creativecomponents/418 
This Creative Component is brought to you for free and open access by the Iowa State University Capstones, 
Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Creative 
Components by an authorized administrator of Iowa State University Digital Repository. For more information, 
please contact digirep@iastate.edu. 
  
 
Therapeutic Potential of Cannabinoids in the Management of Alzheimer’s Disease  
and Other Neurodegenerative Conditions 
 
Lauren Ramos 
 
Iowa State University 
Biomedical Sciences 
Creative Component 
Fall 2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Abstract 
 Alzheimer’s disease (AD) is the most pervasive form of neurodegenerative dementia 
affecting the global population today. Efforts to develop pharmacological intervention to halt or 
reverse the progression of AD have proven unsuccessful, resulting in insufficient treatment 
options for patients with AD which possess limited therapeutic benefits such as symptom 
management and slowing the inevitable progression of the disease. The lack of effective 
medications to treat AD has led to an urgent effort to fill this therapeutic gap, prompting 
researchers to further investigate the proposed anti-inflammatory and neuroprotective properties 
of cannabinoids in neurological diseases. This paper will review the current literature related to 
cannabinoids as potential therapeutic agents in the context of neurodegenerative disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
Introduction 
 Neurodegenerative disease is defined by the slow and chronic progression of neuronal 
loss in specific areas of the nervous system. These types of disorders can affect either motor 
control and movement or cognitive function and dementia. The neurodegeneration associated 
with these types of diseases occurs over an extended period of time, often a decade or more. 
Individuals with a neurodegenerative condition typically do not consciously experience 
symptoms or clinical manifestations of the disease until irreparable cell damage has already 
occurred (Iuvone et al., 2009).  
As a result of today’s aging population, an estimated 115 million people are expected to 
be affected by neurodegenerative disease impacting cognitive function and dementia by the 
year 2050 (Vauzour, 2014). The most common form of neurodegenerative dementia in aging 
individuals is Alzheimer’s disease (AD) (Benito et al., 2008). At present there is no known cure 
for the disease, and the limited treatment options available to AD patients merely slow the 
progression of the disease and aid in managing its symptoms (Jayant et al., 2016). The 
prevalence of this condition in combination with the lack of effective pharmacological 
intervention makes AD one of the most significant global health challenges today. This review 
will discuss the symptoms and hallmark characteristics of AD, the factors that contribute to its 
pathology, and the current research available related to cannabinoids as possible compounds of 
interest in the development of novel therapeutics for patients with AD. 
 
Overview of AD 
 AD is highly prevalent in modern society, with an estimated 35 million people suffering 
from the disease worldwide (Sorrentino et al., 2014). The disease is especially common among 
senior individuals, as aging is the largest risk factor for AD (Sarlus and Heneka, 2017). The 
average age of onset for this debilitating neurodegenerative condition occurs in adults aged 60-
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65 and older (Ahmed et al., 2015). Over time, its progression results in decreased neuronal 
function, cognitive impairment, behavioral deficits, and dementia (Ramirez et al., 2017). 
 Although the precise cause of AD is not well established, several links to understanding 
its complex pathology have been identified. It is widely accepted that there are two pathological 
hallmarks of the disease which are consistently present in brain tissue of individuals afflicted 
with AD. The first is extracellular senile plaques, which are composed of an accumulation of 
misfolded β-amyloid (Aβ) proteins (Sarlus and Heneka, 2017). The second is the presence of 
neurofibrillary tangles, or tau tangles, which contain an accumulation of hyperphosphorylated 
tau protein (Morales et al., 2014).  
 Protein and peptide deposits, microglial activation, neurotoxins, oxidative stress, 
neuronal loss, and progressive cognitive deficiencies have all been closely linked with AD (Watt 
et al., 2017). Many of these factors contribute to a strong, persistent immune response resulting 
in heightened inflammation in the brain (Morales et al., 2014). This neuroinflammation can 
become chronic, a trait shared by many neurodegenerative diseases. This chronic 
neuroinflammation has been widely acknowledged as a major contributor to the 
neurodegeneration associated with AD (Iuvone et al., 2009, Morales et al., 2014). 
Understanding the specific mechanisms underlying the pathology of AD is a crucial step in 
identifying effective targets to alter the progression of the disease as either preventative or 
therapeutic measures. 
 
Overview of Cannabinoids 
Types of Cannabinoids 
 There is increased therapeutic interest in cannabinoids in recent years due to their 
demonstrated neuroprotective and anti-inflammatory properties in various studies. 
Cannabinoids are separated into three distinct categories based on source. The first are 
exogenous or plant-based cannabinoids (also known as phytocannabinoids), then endogenous 
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cannabinoids (or endocannabinoids), and finally manufactured or synthetic cannabinoids 
(Iuvone et al., 2009, du Plessis et al., 2015).  
 The first group are naturally occurring compounds derived from the Cannabis sativa 
plant, more commonly referred to as marijuana (Lu et al., 2017). Recreational use of C. sativa 
has been popular for nearly five thousand years due to its psychoactive and calming properties. 
Byproducts of the plant were first introduced to Western medicine in the nineteenth century and 
were harnessed to treat symptoms ranging from anxiety to fever and pain (Iuvone et al., 2009; 
Lu et al., 2017).  
In the 1930s and 1940s, cannabinol (CBN) and cannabidiol (CBD) were isolated and 
identified as the two major non-psychotropic agents naturally present in C. sativa (Iuvone et al., 
2009, Walter et al., 2003). It was not until the 1960s that the main psychoactive component of 
C. sativa was first isolated and identified as Δ9-tetrahydrocannabinol (THC). This discovery was 
critical in uncovering the endocannabinoid system (Hillard, 2015). Although the use of medicinal 
cannabis remains controversial, its clinical applications have become increasingly 
acknowledged and accepted over time. Phytocannabinoids are currently being clinically 
prescribed in several states in the U.S. and in countries such as Canada, Australia, and Spain  
to mitigate symptoms such as nausea and pain associated with chemotherapy and cancer, 
inhibit spastic movements of patients with multiple sclerosis, and increase the appetite of 
patients suffering from AIDS, among other applications (Lu et al., 2017).  
 The endocannabinoids are those produced by the endocannabinoid system. This system 
modulates nearly every region of the brain and influences many functions of the central nervous 
system (CNS) (Hillard, 2015). This system has been linked to neurodegenerative disorders and 
has been shown to play a complex role in CNS signaling. The system is composed of 
endogenous cannabinoids, degradative and synthetic enzymes that assist in the processing of 
cannabinoids, and cannabinoid receptors (Basavarajappa et al., 2017). Endogenous 
cannabinoids are comprised of lipids that act on cannabinoid receptors and therefore are 
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capable of mimicking some of the physiological actions of THC found in exogenous 
cannabinoids (du Plessis et al., 2015). 
 Synthetic cannabinoids are a family of heterogeneous compounds designed and 
manufactured to stimulate the endocannabinoid system through functional resemblance to THC 
(Antoniou and Juurlink, 2014). For a brief period of time in the early 2000s, synthetic 
cannabinoids such as Spice and K2 gained unfavorable notoriety for providing individuals 
seeking to abuse marijuana with a legal opportunity to achieve similar effects. Since that time, 
scientific studies of various synthetic cannabinoids have demonstrated pharmacological effects 
similar to THC, although vastly more potent, both in vitro and in vivo (Castaneto et al., 2014). 
Cannabinoid Receptor Subtypes 
 All three classifications of cannabinoids achieve their physiological effects on the CNS 
through stimulation of cannabinoid receptors. Two subtypes of cannabinoid receptors are well 
characterized to date: cannabinoid receptor type 1 (CB1R) and type 2 (CB2R) (Basavarajappa 
et al., 2017). Both are transmembrane spanning G-protein coupled receptors (GPCRs) (du 
Plessis et al., 2015). These receptors are coupled to Gi proteins, which have an overall 
inhibitory physiological effect (Iuvone et al., 2009). 
 CB1Rs are considered the predominant cannabinoid receptor of the brain due to the 
high level of expression in the CNS, although they are present in the peripheral nervous system 
as well (Alger, 2014). CB1Rs are located in various regions of the brain including the 
hippocampus, basal ganglia, and cerebellum and are thought to play a regulatory role in 
memory and cognition (Alger, 2014, Talarico et al., 2019). In addition to their neuronal 
presence, CB1Rs are also present in astrocytes and microglia (Ramírez et al., 2005). Activation 
of these receptors is believed to decrease intracellular Ca2+ concentrations, inhibit glutamate 
release (Talarico et al., 2019), enhance GABAergic signaling (Alsasua del Valle, 2006), and 
increase neurotrophin expression and neurogenesis (Talarico et al., 2019). Endogenous, 
exogenous, and synthetic cannabinoids can all act on CB1Rs. Activation of these receptors by 
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cannabinoids has demonstrated neuroprotective effects in various studies (Benito et al., 2008). 
However, CB1Rs are also responsible for mediating the psychoactive effects of cannabinoids, 
thereby complicating and greatly limiting the pharmacological possibilities of CB1R as a 
potential drug target (Maldonado et al., 2011). 
 CB2Rs, while substantially less abundant in the CNS, appear to play an interesting role 
in neurodegenerative disease (Talarico et al., 2019). They are primarily located in the periphery, 
specifically in cells and tissues of the immune system (Benito et al., 2008). However, they also 
have limited presence in the brain and have been found in microglial cells (Talarico et al., 2019). 
Interestingly, recent studies found that CB2Rs were significantly upregulated in microglia 
surrounding senile plaques in the hippocampus of post-mortem AD brains (Talarico et al., 
2019), suggesting that these receptors may be involved in the inflammatory pathway of AD (Aso 
et al., 2016). In contrast to CB1Rs, CB2R activation is not associated with psychoactive effects, 
making this receptor subtype a more desirable therapeutic candidate than CB1Rs (Buckley et 
al., 2000). In addition, CB2Rs have demonstrated an ability to be manipulated under 
neuroinflammatory conditions whereas CB1Rs have not, further promoting increased interest in 
CB2Rs as a potential therapeutic target for the treatment of neurodegenerative disease (Benito 
et al., 2008). 
  
Current Literature on AD Pathology and Cannabinoids 
Effect of Cannabinoids on Immune Function and Microglial Activation 
In recent years, cannabinoids have been shown to decrease Aβ-induced microglial 
activation and modulate microglial activity, thereby preventing neuroinflammation (Schmöle et 
al., 2018). Microglia are resident immune cells of the brain and function to detect assaults on the 
CNS and defend against attacks by initiating an immune response. They also serve a protective 
role in the brain by promoting phagocytosis, assisting in tissue repair, and maintaining cerebral 
homeostasis. Microglial detection of CNS damage prompts glial cells to undergo various 
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phenotypical and secretory changes resulting in what is referred to as an “activated state” 
(Sarlus and Heneka, 2017). Two different types of microglial activation can occur. 
 One phenotype, M1 activation, involves an extensive inflammatory response including 
the release of inducible nitric oxide synthase (iNOS) as well as the release of pro-inflammatory 
substances such as cytokines, chemokines, and interleukins. Microglia in an M1 state of 
activation demonstrate increased motility and enhanced phagocytic activity. Under specific 
conditions, M1 activated microglia can clear protein aggregates and other unwanted materials 
from the brain. M1 microglia can eventually reach a state of unchecked activation, resulting in 
continuous neuroinflammation. This chronic M1 activation generates an unrelenting release of 
neurotoxic factors (pro-inflammatory substances, nitric oxide (NO), hydrogen peroxide, and 
glutamate), further exacerbating local cell damage and contributing to neuronal death and 
degeneration (Walter et al., 2003; Ramírez et al., 2017). This state of reactive gliosis is widely 
accepted to be a key factor in AD pathology (Sarlus and Heneka, 2017). 
 In contrast, microglia activated in the M2 phenotype serve a restorative anti-
inflammatory role. M2 microglia function to reestablish a homeostatic environment in the brain 
and release anti-inflammatory cytokines and interleukins, thereby alleviating neuroinflammation. 
Actions of M2 microglia promote the expression of repair genes and stimulate neuronal growth 
and survival. Microglia possess the ability to change from the M2 to the M1 state throughout the 
progression of various neurological diseases, thereby changing the landscape of inflammation 
in the brain (Cherry et al., 2014; Ramírez et al., 2017).  
Once pathological concentrations of misfolded Aβ protein are reached in the early-stage 
AD brain, microglia detect the conditions as harmful and enter an M1 activated state. These M1 
microglial cells then initiate a fierce immune response involving the activation of complement, 
cytokine release, neurotoxic secretions, and phagocytosis in an effort to remove damaging Aβ 
deposits from the brain (Ramírez et al., 2005; Martín-Moreno et al., 2011; Akiyama et al., 2000). 
Significant chronic neuroinflammation develops as a result of M1 activation, leading to the 
8 
characteristic hyperphosphorylation of the tau protein and subsequent accumulation of 
neurofibrillary tangles associated with AD (Serrano-Pozo et al., 2011). The inflammation also 
triggers M1 microglia to migrate toward dying neurons, resulting in increased cell damage in the 
brain (Walter et al., 2003).  
Aβ-induced M1 activation is therefore widely considered to be a significant contributor to 
the vicious cycle of immune activity that results in chronic neuroinflammation and ultimately 
neurodegeneration (Kreisl, 2017). As a result, there has been heightened therapeutic interest in 
pharmacologically inhibiting M1 microglial activation in an effort to reduce the intensity of the 
immune response and prevent the subsequent chronic neuroinflammation which results in 
neurodegenerative conditions (Martín-Moreno et al., 2011). 
 Although CB2Rs do appear to play a role in the neuroinflammatory process, the 
underlying mechanisms responsible for these actions are poorly understood at present, as both 
the genetic deletion and pharmacological activation of CB2Rs have been shown to reduce 
neuroinflammation (Schmöle et al., 2018). A CB2R agonist (JWH-133) has been shown to 
significantly decrease neurological impairment, mitigate the intensity of microglia and 
macrophage activity, and decrease the gene expression of markers for microglial and 
macrophage activation in an in vivo mouse model of infarction, thereby contributing to a reduced 
immune response (Zarruk et al., 2012). When exposed to a mouse model of AD, CBD also 
decreased cytokine expression resulting in a reduced neuroinflammatory response in vivo. In 
addition, CBD, which can act on both CB1Rs and CB2Rs, successfully blocked microglial 
activation in vitro, preventing the migration of microglia toward dying cells and eliminating their 
potential to further exacerbate destruction of these neurons (Martín-Moreno et al., 2011).  
Martín-Moreno also demonstrated that CB2R agonists have the ability to decrease free 
radical NO production and reduce harmful levels of oxidative stress affecting Aβ-exposed 
microglia in culture (Martín-Moreno et al., 2011). Another CB2R-selective agonist (JWH-015) 
effectively decreased immune activity by limiting microglial production of TNF-α and NO, 
9 
thereby reducing levels of pro-inflammatory substances released in the brain (Ehrhart et al., 
2005). CBD also reduced factors related to oxidative stress and apoptosis in an in vivo model of 
newborn mice, further supporting the neuroprotective capabilities of cannabinoids (Castillo et 
al., 2009).  
 A study utilizing an AD model in mice found that microglial cells harvested from CB2R 
negative mice were less responsive to pro-inflammatory stimuli than microglia harvested from 
CB2R positive mice. The transgenic mice lacking CB2R also had lower percentages of microglia 
and macrophages, reduced expression of pro-inflammatory chemokines and cytokines in the 
brain, and reduced concentrations of Aβ peptides, again suggesting CB2R likely plays a role in 
neuroinflammation (Schmöle et al., 2015). THC has also been shown to successfully reduce 
immune activity by inhibiting macrophage functions in vivo in wild type mice but not in CB2R 
knockout mice, indicating that phagocytic action may be mediated by CB2Rs (Buckley et al., 
2000). 
 Treatment with a CB2R-selective modulator (1-phenylisatin) also significantly reduced 
neuroinflammation and neuronal damage and reduced Aβ deposits in vivo in two different 
mouse models of AD (Jayanat et al., 2016). CB2R modulators have also been shown to play a 
role in the migration of activated microglia. One endocannabinoid, 2-arachidonylglycerol (2-AG) 
triggered microglial motility and has been found to be mediated by CB2Rs. CBN and CBD both 
prevented 2-AG-induced microglial migration by acting as CB2R antagonists, suggesting the 
cannabinoid signaling system may be involved in the regulation of microglial migration (Walter 
et al., 2003).  
Effect of Cannabinoids on Tau Hyperphosphorylation and Aβ Deposition 
Cannabinoids have also demonstrated the ability to modulate tau hyperphosphorylation 
and Aβ accumulation and deposition. CB1R agonists have been shown to protect against tau 
hyperphosphorylation both in vivo and in cultured neurons, thereby preventing the formation of 
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neurofibrillary tangles. CB1R agonists also mitigated cellular changes and behavioral 
consequences in Aβ-induced mice (Iuvone et al., 2003).  
A study analyzing post-mortem AD brain tissue indicated that CB2R expression levels 
were nearly 40% higher in individuals with AD compared to an age-matched control. Many of 
these CB2Rs were found surrounding senile plaques in subjects with AD. CB2R levels were 
also positively correlated with both Aβ protein levels and senile plaque score in post-mortem AD 
coritcal brain tissues (Solas et al., 2013), providing strong evidence that CB2Rs may play a 
functional role in Aβ accumulation.  
Schmöle et al. showed that CB2R deletion in mice expressing genetic variants of 
amyloid precursor protein (APP), an Aβ precursor, resulted in neuroprotection by decreasing 
neuronal loss, lowering senile plaque levels, and correlating with increased Aβ degrading 
enzyme expression (Schmöle et al., 2018).  Activation of CB2R by selective agonist JWH-015 
also resulted in neuroprotective effects in vitro by reducing the expression of a tumor necrosis 
factor receptor (CD40) which is directly correlated with Aβ peptide levels. In addition, JWH-015 
enhanced microglial phagocytosis of Aβ by suppressing inhibition efforts mediated by CD40 in 
vitro (Ehrhart et al., 2005). 
A study by Scuderi et al. indicated that CBD may also be capable of decreasing APP, 
thereby hindering Aβ formation and diminishing its potential to activate microglia (Scuderi et al., 
2013). Iuvone et al. established that CBD-treated cells provided neuroprotection in vitro by 
significantly increasing cell survival following Aβ exposure and provided protection against 
oxidative stress and apoptotic effects associated with Aβ toxicity (Iuvone et al., 2004). Vallée et 
al. also demonstrated that CBD inhibits Aβ-induced tau hyperphosphorylation and inhibits 
another Aβ precursor, thereby decreasing Aβ levels overall. This study also supports the 
mitigating effects of CBD on oxidative stress, reactive oxygen species production, and pro-
inflammatory signaling (Vallée et al., 2017). 
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Additionally, current literature indicates that cannabinoids may play a role in memory 
function and cognitive deficits. A study by Albayram et al. showed that mice lacking CB1Rs had 
increased neuroinflammation in the hippocampus, suggesting that CB1R activity on GABAergic 
neurons in the hippocampus may protect against age-dependent dementia-like cognitive decline 
by reducing neuroinflammation (Albayram et al., 2011). Similarly, the genetic deletion of CB1Rs 
also led to accelerated memory impairment in transgenic CB1 knockout mice, reinforcing the 
notion that CB1Rs may play a critical role in the progression of AD-related pathology (Aso et al., 
2016).  
The role of CB2Rs in memory and cognitive functioning again appears to be 
mechanistically complex. CB2R activation has been shown to improve cognitive impairment in 
animal models of AD (Aso et al., 2016). Similarly, Jayant et al. demonstrated that a selective 
CB2R agonist (1-phenylisatin) was able to successfully mitigate learning-memory impairment in 
vivo in an AD model in mice (Jayant et al., 2016). However, Schmöle et al. reported 
improvements in cognitive and learning deficits following CB2R deletion in mouse models 
expressing APP (Schmöle et al., 2018). This data reinforces that CB2Rs do appear to play a 
role in memory and cognition, although their precise mechanism of action still requires further 
investigation. 
Administration of a synthetic cannabinoid, WIN55,212-2, by Ramírez et al. prevented 
cognitive impairment and loss of neuronal markers in rats (Ramírez et al., 2005). CBD has also 
demonstrated the ability to both prevent and reverse the progression of cognitive impairment in 
rodent models of AD (Watt et al., 2017). A new study shows that cells pre-treated with CBD 
yielded neuroprotective effects against Aβ-mediated hippocampal long-term potentiation (LTP), 
which is a common cellular mechanistic standard used in the study of memory (Hughes et al., 
2019). Another study by Fagherazzi et al. demonstrated that a single high dose injection of CBD 
was able to rescue memory in rats with iron-induced memory impairment. Chronic CBD 
administration also demonstrated improved recognition memory in iron-treated rats, suggesting 
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the potential use of CBD in the treatment of cognitive deficiencies associated with 
neurodegenerative disease (Fagherazzi et al., 2011).  
 
Conclusion 
Current research suggests that cannabinoids may be a promising therapeutic candidate 
for prevention and protection against neurodegenerative diseases such as AD in the future. 
Cannabinoids have demonstrated wide-ranging beneficial neuroprotective and therapeutic 
effects related to Aβ levels, tau hyperphosphorylation, immune activity, neuroinflammation, 
neuronal loss, and cognition. Recent studies indicate that cannabinoids may be a source of 
continued therapeutic focus for conditions related to inflammatory conditions and 
neurodegenerative disease. 
Future studies are necessary in order to better understand the mechanistic actions and 
therapeutic potential of cannabinoids in treating conditions related to neurodegenerative 
disease. Although research related to cannabinoids in cell culture and in animal models of AD is 
available, clinical studies of cannabinoids as therapeutic targets in humans are scarce. These 
studies are necessary to better understand the effects of various cannabinoids in humans with 
AD pathology. Research related to long-term safety and efficacy of medicinal cannabinoids in 
humans moving forward is also an area of great need, particularly related to newer 
cannabinoids such as CBD and synthetic cannabinoids, which have very little long-term data 
available at present. Although significant research remains to be done, cannabinoids have 
proven to promising therapeutic potential in the treatment of AD and other inflammatory and 
neurodegenerative conditions.  
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